A study of epidemiology, clinical features and co-morbidities in psoriasis

 

Nachiket Palaskar¹, Pralhad R Rathod^2*

 

REFERENCES

1. Whan B. Kim, Dana Jerome, Jensen Yeung. Diagnosis and management of psoriasis. Canadian Family Physician. 2017 April; 63(4): 278-285.
2. Finlay AY, Kelly SE. Psoriasis—an index of disability. Clin Exp Dermatol 1987; 12:8–11.
3. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000;43:281–5
4. A. Ejaz, N. Raza, N. Iftikhar, A. Iftikhar, and M. Farooq, “Presentation of early onset psoriasis in comparison with late onset psoriasis: A clinical study from Pakistan,” Indian Journal of Dermatology, Venereology and Leprology, vol. 75, no. 1, pp. 36–40, 2009.
5. Y. T. Chang, T. J. Chen, P. C. Liu et al., “Epidemiological study of psoriasis in the national health insurance database in Taiwan,” Acta Dermato-Venereologica, vol. 89, no. 3, pp. 262–266, 2009.
6. R. Parisi, D. P. M. Symmons, C. E. M. Griffiths, and D. M. Ashcroft, “Global epidemiology of psoriasis: a systematic review of incidence and prevalence,” Journal of Investigative Dermatology, vol. 133, no. 2, pp. 377–385, 2013. 
7. X. Ding, T. Wang, Y. Shen, X. Wang, C. Zhou, and S. Tian, “Prevalence of psoriasis in China: a population-based study in six cities,” European Journal of Dermatology, vol. 22, no. 5, pp. 663–667, 2012.
8. K. Bo, M. Thoresen, and F. Dalgard, “Smokers report more psoriasis, but not atopic dermatitis or hand eczema: Results from a Norwegian population survey among adults,” Dermatology, vol. 216, pp. 40–45, 2008. 
9. Marsa S, Armadans-Gil L, Martinez M, Gallardo D, Ribera A, Lience E. Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis. Rheumatology. 1999;38:332–7
10. Veale D, Rogers S, Fiztgerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol. 1994;33:133–8.
11. A. Buske-Kirschbaum, M. Ebrecht, S. Kern, and D. H. Hellhammer, “Endocrine stress responses in TH1-mediated chronic inflammatory skin disease (psoriasis vulgaris)—do they parallel stress-induced endocrine changes in TH2-mediated inflammatory dermatoses (atopic dermatitis)?” Psychoneuroendocrinology, vol. 31, no. 4, pp. 439–446, 2006.
12. A. W. M. Evers, Y. Lu, P. Duller, P. G. M. Van Der Valk, F. W. Kraaimaat, and P. C. M. Van De Kerkhoft, “Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis,” British Journal of Dermatology, vol. 152, no. 6, pp. 1275–1281, 2005.
13. A. W. M. Evers, E. W. M. Verhoeven, F. W. Kraaimaat et al., “How stress gets under the skin: Cortisol and stress reactivity in psoriasis,” British Journal of Dermatology, vol. 163, no. 5, pp. 986–991, 2010. 
14. J. Hayes and J. Koo, “Psoriasis: Depression, anxiety, smoking, and drinking habits,” Dermatologic Therapy, vol. 23, no. 2, pp. 174–180, 2010
15. A. D. Cohen, M. Sherf, L. Vidavsky, D. A. Vardy, J. Shapiro, and J. Meyerovitch, “Association between psoriasis and the metabolic syndrome: A cross-sectional study,” Dermatology, vol. 216, no. 2, pp. 152–155, 2008. 
16. J. Shapiro, A. D. Cohen, M. David et al., “The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: A case-control study,” Journal of the American Academy of Dermatology, vol. 56, no. 4, pp. 629–634, 2007.